Drugs & Aging

, Volume 23, Issue 6, pp 461–489 | Cite as

Practical Considerations for the Treatment of Elderly Patients with Migraine

  • Paola Sarchielli
  • Maria Luisa Mancini
  • Paolo Calabresi
Therapy In Practice


Treatment of migraine presents special problems in the elderly. Co-morbid diseases may prohibit the use of some medications. Moreover, even when these contraindications do not exist, older patients are more likely than younger ones to develop adverse events. Managing older migraine patients, therefore, necessitates particular caution, including taking into account possible pharmacological interactions associated with the greater use of drugs for concomitant diseases in the elderly.

Paracetamol (acetaminophen) is the safest drug for symptomatic treatment of migraine in the elderly. Use of selective serotonin 5-HT1B/1D receptor agonists (‘triptans’) is not recommended, even in the absence of cardiovascular or cerebrovascular risk, and NSAID use should be limited because of potential gastrointestinal adverse effects.

Prophylactic treatments include antidepressants, β-adrenoceptor antagonists, calcium channel antagonists and antiepileptics. Selection of a drug from one of these classes should be dictated by the patient’s co-morbidities. β-Adrenoceptor antagonists are appropriate in patients with hypertension but are contraindicated in those with chronic obstructive pulmonary disease, diabetes mellitus, heart failure and peripheral vascular disease. Use of antidepressants in low doses is, in general, well tolerated by elderly people and as effective, overall, as in young adults. This approach is preferred in patients with concomitant mood disorders. However, prostatism, glaucoma and heart disease make the use of tricyclic antidepressants more difficult. Fewer efficacy data in the elderly are available for selective serotonin reuptake inhibitors, which can be tried in particular cases because of their good tolerability profile. Calcium channel antagonists are contraindicated in patients with hypotension, heart failure, atrioventricular block, Parkinson’s disease or depression (flunarizine), and in those taking β-adrenoceptor antagonists and monoamine oxidase inhibitors (verapamil). Antiepileptic drug use should be limited to migraine with high frequency of attacks and refractoriness to other treatments. Promising additional strategies include ACE inhibitors and angiotensin II type 1 receptor antagonists because of their effectiveness and good tolerability in patients with migraine, particularly in those with hypertension. Because of its favourable compliance and safety profile, botulinum toxin type A can be considered an alternative treatment in elderly migraine patients who have not responded to other currently available migraine prophylactic agents.

Pharmacological treatment of migraine poses special problems in regard to both symptomatic and prophylactic treatment. Contraindications to triptan use, adverse effects of NSAIDs, and unwanted reactions to some antiemetics reduce the list of drugs available for the treatment of migraine attacks in elderly patients. The choice of prophylactic treatment (β-adrenoceptor antagonists, calcium channel antagonists, antiepileptics, and more recently, some antihypertensive drugs) is influenced by co-morbidities and should be directed at those drugs that are believed to have fewer adverse effects and a better safety profile. Unfortunately, for most of these drugs, efficacy studies are lacking in the elderly.



The authors declare no sources of funding were used to assist in the preparation of the manuscript. They also declare no potential conflicts of interest that are directly relevant to the contents of the manuscript.

The authors would like to thank Dr Costante Donati Sarti of the Obstetrics and Gynecology Clinic of the University of Perugia for his critical review and suggestions concerning the section on hormone replacement therapy.

The authors express their gratitude to John A. Toomey for editing the English and Marisa M. Morson for technical assistance.


  1. 1.
    Prencipe M, Casini AR, Ferretti C, et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 2001; 70(3): 377–81PubMedCrossRefGoogle Scholar
  2. 2.
    Camarda R, Monastero R. Prevalence of primary headaches in Italian elderly: preliminary data from the Zabut Aging Project. Neurol Sci 2003; 24Suppl. 2: S122–S4PubMedGoogle Scholar
  3. 3.
    Wang SJ, Liu HC, Fuh JL, et al. Prevalence of headaches in a Chinese elderly population in Kinmen: age and gender effect and cross-cultural comparisons. Neurology 1997; 49(1): 195–200PubMedCrossRefGoogle Scholar
  4. 4.
    Lipton RB, Pfeffer D, Newman LC, et al. Headaches in the elderly. J Pain Symptom Manage 1993; 8(2): 87–97PubMedCrossRefGoogle Scholar
  5. 5.
    Chatap G, Giraud K, Vincent JP, et al. Headaches in the elderly [in French]. Presse Med 2004; 33 (12 Pt 1): 808–18PubMedCrossRefGoogle Scholar
  6. 6.
    Edmeads J, Wang SJ. Headaches in the elderly. In: Olesen J, Goadsby P, Ramadan NM, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 1105–10Google Scholar
  7. 7.
    Edmeads J. Headaches in older people: how are they different in this age-group? Postgrad Med 1997; 101(5): 91–4, 98–100PubMedGoogle Scholar
  8. 8.
    Biondi DM, Saper JR. Geriatric headache: how to make the diagnosis and manage the pain. Geriatrics 2000; 55(12): 40, 43–5, 48–50PubMedGoogle Scholar
  9. 9.
    Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 2003; 60(6): 905–9PubMedCrossRefGoogle Scholar
  10. 10.
    Mattsson P, Svardsudd K, Lundberg PO, et al. The prevalence of migraine in women aged 40–70 years: a population-based study. Cephalalgia 2000; 20(10): 893–9PubMedCrossRefGoogle Scholar
  11. 11.
    Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994; 34Suppl. 2: 6–11PubMedCrossRefGoogle Scholar
  12. 12.
    Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. JAMA 1992; 267(1): 64–9PubMedCrossRefGoogle Scholar
  13. 13.
    Cull RE. Investigation of late-onset migraine. Scott Med J 1995; 40(2): 50–2PubMedGoogle Scholar
  14. 14.
    Mazzotta G, Gallai V, Alberti A, et al. Characteristics of migraine in an out-patient population over 60 years of age. Cephalalgia 2003; 23(10): 953–60PubMedCrossRefGoogle Scholar
  15. 15.
    Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47(4): 871–5PubMedCrossRefGoogle Scholar
  16. 16.
    Fisher CM. Late-life (migrainous) scintillating zigzags without headache: one person’s 27-year experience. Headache 1999; 39(6): 391–7PubMedCrossRefGoogle Scholar
  17. 17.
    Martins KM, Bordini CA, Bigal ME, et al. Migraine in the elderly: a comparison with migraine in young adults. Headache 2006; 46(2): 312–6PubMedCrossRefGoogle Scholar
  18. 18.
    Wynne H. Drug metabolism and ageing. J Br Menopause Soc 2005; 11(2): 51–6PubMedCrossRefGoogle Scholar
  19. 19.
    Rankin LM, Bruhl M. Migraine in older patients: a case report and management strategies. Geriatrics 2000; 55(7): 70–4PubMedGoogle Scholar
  20. 20.
    Landy S. Migraine throughout the life cycle: treatment through the ages. Neurology 2004; 62 (5 Suppl. 2): S2–8PubMedCrossRefGoogle Scholar
  21. 21.
    Pietrini U, De Luca M, De Santis G. Hypertension in headache patients? A clinical study. Acta Neurol Scand 2005; 112(4): 259–64PubMedCrossRefGoogle Scholar
  22. 22.
    Tzourio C, Gagniere B, El Amrani M, et al. Relationship between migraine, blood pressure and carotid thickness: a population-based study in the elderly. Cephalalgia 2003; 23(9): 914–20PubMedCrossRefGoogle Scholar
  23. 23.
    Gilbert GJ. Cardiac cephalgia. Neurology 1998; 50(3): 836PubMedCrossRefGoogle Scholar
  24. 24.
    Green MW. A spectrum of exertional headaches. Med Clin North Am 2001; 85(4): 1085–92PubMedCrossRefGoogle Scholar
  25. 25.
    Cook NR, Bensenor IM, Lotufo PA, et al. Migraine and coronary heart disease in women and men. Headache 2002; 42(8): 715–27PubMedCrossRefGoogle Scholar
  26. 26.
    Logroscino G, Lipton RB. Migraine is associated with chest symptoms but not cardiac events: a reassuring paradox [letter]. Neurology 2004; 63(12): 2209–10PubMedCrossRefGoogle Scholar
  27. 27.
    O’Keeffe ST, Tsapatsaris NP, Beetham Jr WP. Association between Raynaud’s phenomenon and migraine in a random population of hospital employees. J Rheumatol 1993; 20(7): 1187–8PubMedGoogle Scholar
  28. 28.
    Rosamond W. Are migraine and coronary heart disease associated? An epidemiologic review. Headache 2004; 44Suppl. 1: S5–S12PubMedCrossRefGoogle Scholar
  29. 29.
    Etminan M, Takkouche B, Isorna FC, et al. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies [published erratum appears in BMJ 2005; 330 (7487): 345; BMJ 2005; 330 (7491): 596]. BMJ 2005; 330(7482): 63PubMedCrossRefGoogle Scholar
  30. 30.
    Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005; 64(6): 1020–6PubMedCrossRefGoogle Scholar
  31. 31.
    Bousser MG, Welch KM. Relation between migraine and stroke. Lancet Neurol 2005; 4(9): 533–42PubMedCrossRefGoogle Scholar
  32. 32.
    Wiehe M, Fuchs SC, Moreira LB, et al. Migraine is more frequent in individuals with optimal and normal blood pressure: a population-based study. J Hypertens 2002; 20(7): 1303–6PubMedCrossRefGoogle Scholar
  33. 33.
    Silvestrini M. Migrainous stroke and antiphospholipid antibodies: are they pathogenetically linked? [letter]. Eur Neurol 1996; 36(2): 114PubMedCrossRefGoogle Scholar
  34. 34.
    Tietjen GE. The risk of stroke in patients with migraine and implications for migraine management. CNS Drugs 2005; 19(8): 683–92PubMedCrossRefGoogle Scholar
  35. 35.
    Crassard I, Conard J, Bousser MG. Migraine and haemostasis. Cephalalgia 2001; 21(6): 630–6PubMedCrossRefGoogle Scholar
  36. 36.
    Diener HC, Weimar C, Katsarava Z. Patent foramen ovale: paradoxical connection to migraine and stroke. Curr Opin Neurol 2005; 18(3): 299–304PubMedCrossRefGoogle Scholar
  37. 37.
    Kruit MC, Launer LJ, van Buchem MA, et al. MRI findings in migraine [in French]. Rev Neurol (Paris) 2005; 161(6–7): 661–5CrossRefGoogle Scholar
  38. 38.
    Goadsby PJ. Is migraine a progressive disorder? Considering the clinical implications of new research data on migraine and brain lesions. Med J Aust 2005; 182(3): 103–4PubMedGoogle Scholar
  39. 39.
    Khaghan N, Holt PR. Peptic disease in elderly patients. Can J Gastroenterol 2000; 14(11): 922–8PubMedGoogle Scholar
  40. 40.
    Pilotto A. Aging and upper gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004; 18 Suppl.: 73–81PubMedCrossRefGoogle Scholar
  41. 41.
    Alexopoulos GS. Depression in the elderly. Lancet 2005; 365(9475): 1961–70PubMedCrossRefGoogle Scholar
  42. 42.
    Wang SJ, Liu HC, Fuh JL, et al. Comorbidity of headaches and depression in the elderly. Pain 1999; 82(3): 239–43PubMedCrossRefGoogle Scholar
  43. 43.
    de Bock GH, Eelhart J, van Marwijk HW, et al. A postmarketing study of flunarizine in migraine and vertigo. Pharm World Sci 1997; 19(6): 269–74PubMedCrossRefGoogle Scholar
  44. 44.
    Ellison KE, Gandhi G. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 2005; 65(6): 787–97PubMedCrossRefGoogle Scholar
  45. 45.
    Becker WJ. Evidence based migraine prophylactic drug therapy. Can J Neurol Sci 1999; 26Suppl. 3: 27S–32SGoogle Scholar
  46. 46.
    Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997; 17(6): 446–50PubMedCrossRefGoogle Scholar
  47. 47.
    Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73(4): 207–15PubMedCrossRefGoogle Scholar
  48. 48.
    Higelin F, Annoni JM. Medical treatment of migraine: from mechanisms of action to contraindications. Schweiz Med Wochenschr 1998; 128(10): 374–83PubMedGoogle Scholar
  49. 49.
    Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005; 45(10): 1106–22PubMedCrossRefGoogle Scholar
  50. 50.
    Petrovic M, De Paepe P, Van Bortel L. Pharmacotherapy of depression in old age. Acta Clin Belg 2005; 60(3): 150–6PubMedGoogle Scholar
  51. 51.
    Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006; 60(4): 482–91PubMedCrossRefGoogle Scholar
  52. 52.
    Briesacher BA, Stuart B, Peluso R. Drug use and prescribing problems in the community-dwelling elderly: a study of three state Medicaid programs. Clin Ther 1999; 21(12): 2156–72PubMedCrossRefGoogle Scholar
  53. 53.
    Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001; 15(2): 105–18PubMedCrossRefGoogle Scholar
  54. 54.
    Avoiding drug interactions. Prescrire Int 2004; 13(71): 99–102Google Scholar
  55. 55.
    Toth C. Medications and substances as a cause of headache: a systematic review of the literature. Clin Neuropharmacol 2003; 26(3): 122–36PubMedCrossRefGoogle Scholar
  56. 56.
    Landy SH. Challenging or difficult headache patients. Prim Care 2004; 31(2): 429–40PubMedCrossRefGoogle Scholar
  57. 57.
    Blanchard EB, Andrasik F, Evans DD, et al. Biofeedback and relaxation treatments for headache in the elderly: a caution and a challenge. Biofeedback Self Regul 1985; 10(1): 69–73PubMedCrossRefGoogle Scholar
  58. 58.
    Kabela E, Blanchard EB, Appelbaum KA, et al. Self-regulatory treatment of headache in the elderly. Biofeedback Self Regul 1989; 14(3): 219–28PubMedCrossRefGoogle Scholar
  59. 59.
    Ad Hoc Committee of the Italian Society for the Study of Headaches (SISC). Diagnostic and therapeutic guidelines for migraine and cluster headache. J Headache Pain 2001; 2(3): 105–92CrossRefGoogle Scholar
  60. 60.
    Blau JN. Migraine triggers: practice and theory [in French]. Pathol Biol (Paris) 1992; 40(4): 367–72Google Scholar
  61. 61.
    Sheftell FD, Cady RK, Borchert LD, et al. Optimizing the diagnosis and treatment of migraine. J Am Acad Nurse Pract 2005; 17(8): 309–17PubMedCrossRefGoogle Scholar
  62. 62.
    Deleu D, Hanssens Y, Worthing EA. Symptomatic and prophylactic treatment of migraine: a critical reappraisal. Clin Neuropharmacol 1998; 21(5): 267–79PubMedGoogle Scholar
  63. 63.
    Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia 1995; 15Suppl. 15: 14–20PubMedGoogle Scholar
  64. 64.
    Peterson GM. Selecting nonprescription analgesics. Am J Ther 2005; 12(1): 67–79PubMedCrossRefGoogle Scholar
  65. 65.
    Ohnishi A, Murakami S, Akizuki S, et al. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol 2005; 45(11): 1221–9PubMedCrossRefGoogle Scholar
  66. 66.
    Lauterburg BH. Analgesics and glutathione. Am J Ther 2002; 9(3): 225–33PubMedCrossRefGoogle Scholar
  67. 67.
    Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12(2): 133–41PubMedCrossRefGoogle Scholar
  68. 68.
    Diener HC, Limmroth V. Analgesics. Curr Med Res Opin 2001; 17Suppl. 1: 13S–6SCrossRefGoogle Scholar
  69. 69.
    Rasmussen MK, Binzer M. Non-steroidal anti-inflammatory drugs in the treatment of migraine. Curr Med Res Opin 2001; 17Suppl. 1: 26S–9SCrossRefGoogle Scholar
  70. 70.
    Wenzel RG, Sarvis CA, Krause ML. Over-the-counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy 2003; 23(4): 494–505PubMedCrossRefGoogle Scholar
  71. 71.
    Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006; 20(2): 143–51PubMedCrossRefGoogle Scholar
  72. 72.
    Go MF. Drug injury in the upper gastrointestinal tract: nonsteroidal anti-inflammatory drugs. Gastrointest Endosc Clin N Am 2006; 16(1): 83–97PubMedCrossRefGoogle Scholar
  73. 73.
    Herings RM, Goettsch WG. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother 2004; 38(5): 760–3PubMedCrossRefGoogle Scholar
  74. 74.
    Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29(3): 467–73PubMedGoogle Scholar
  75. 75.
    Rybar I, Masaryk P, Mateicka F, et al. Nonsteroidal antiinflammatory drug-induced mucosal lesions of the upper gastrointestinal tract and their relationship to Helicobacter pylori. Int J Clin Pharmacol Res 2001; 21(3–4): 119–25PubMedGoogle Scholar
  76. 76.
    Hawkey CJ, Fortun PJ. Cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2005; 21(6): 660–4PubMedGoogle Scholar
  77. 77.
    Krymchantowski AV, Bigal ME. Rofecoxib in migraine. Expert Rev Neurother 2005; 5(1): 55–61PubMedCrossRefGoogle Scholar
  78. 78.
    Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J 2004; 80(950): 720–3PubMedCrossRefGoogle Scholar
  79. 79.
    Krotz F, Schiele TM, Klauss V, et al. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005; 42(4): 312–24PubMedCrossRefGoogle Scholar
  80. 80.
    Batty GM, Oborne CA, Swift CG, et al. The use of over-the-counter medication by elderly medical in-patients. Postgrad Med J 1997; 73(865): 720–2PubMedCrossRefGoogle Scholar
  81. 81.
    Francis SA, Barnett N, Denham M. Switching of prescription drugs to over-the-counter status: is it a good thing for the elderly? Drugs Aging 2005; 22(5): 361–70PubMedCrossRefGoogle Scholar
  82. 82.
    Ward TN. Medication overuse headache. Prim Care 2004; 31(2): 369–80PubMedCrossRefGoogle Scholar
  83. 83.
    Bigal ME, Sheftell FD, Rapoport AM, et al. Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002; 42(7): 575–81PubMedCrossRefGoogle Scholar
  84. 84.
    Grazzi L, Andrasik F. Medication-overuse headache: description, treatment, and relapse prevention. Curr Pain Headache Rep 2006; 10(1): 71–7PubMedCrossRefGoogle Scholar
  85. 85.
    Poole C, Jones D, Veitch B. Relationships between prescription and non-prescription drug use in an elderly population. Arch Gerontol Geriatr 1999; 28(3): 259–71PubMedCrossRefGoogle Scholar
  86. 86.
    Roumie CL, Griffin MR. Over-the-counter analgesics in older adults: a call for improved labelling and consumer education. Drugs Aging 2004; 21(8): 485–98PubMedCrossRefGoogle Scholar
  87. 87.
    Neubauer DN. Sleep problems in the elderly. Am Fam Physician 1999; 59(9): 2551–8, 2559–60PubMedGoogle Scholar
  88. 88.
    Smith A. Effects of caffeine on human behavior. Food Chem Toxicol 2002; 40(9): 1243–55PubMedCrossRefGoogle Scholar
  89. 89.
    Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs 2005; 19(9): 769–84PubMedCrossRefGoogle Scholar
  90. 90.
    Wilder-Smith OH. Opioid use in the elderly. Eur J Pain 2005; 9(2): 137–40PubMedCrossRefGoogle Scholar
  91. 91.
    Silberstein SD, McCrory DC. Opioids. Cephalalgia 2000; 20(10): 854–64PubMedCrossRefGoogle Scholar
  92. 92.
    Ziegler DK. Opioids in headache treatment: is there a role? Neurol Clin 1997; 15(1): 199–207PubMedCrossRefGoogle Scholar
  93. 93.
    Adelman JU, Lewit EJ. Comparative aspects of triptans in treating migraine. Clin Cornerstone 2001; 4(3): 53–64PubMedCrossRefGoogle Scholar
  94. 94.
    Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003; 17(6): 431–47PubMedCrossRefGoogle Scholar
  95. 95.
    Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003; 2(2): 123–32PubMedCrossRefGoogle Scholar
  96. 96.
    Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62(4): 563–8PubMedCrossRefGoogle Scholar
  97. 97.
    Dodick D, Lipton RB, Martin V, et al., on behalf of the Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004; 44(5): 414–25PubMedCrossRefGoogle Scholar
  98. 98.
    Papademetriou V. Cardiovascular risk assessment and triptans. Headache 2004; 44Suppl. 1: 31S–9SCrossRefGoogle Scholar
  99. 99.
    Tepper S, Allen C, Sanders D, et al. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003; 43(1): 44–8PubMedCrossRefGoogle Scholar
  100. 100.
    MacGregor EA. Anti-emetics. Curr Med Res Opin 2001; 17Suppl. 1: 22S–5SCrossRefGoogle Scholar
  101. 101.
    Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997; 16(3): 180–204PubMedCrossRefGoogle Scholar
  102. 102.
    Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology (Berl) 1996; 128(1): 67–73CrossRefGoogle Scholar
  103. 103.
    Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003; 39(7): 551–7CrossRefGoogle Scholar
  104. 104.
    Gladstone JP, Eross EJ, Dodick DW. Migraine in special populations: treatment strategies for children and adolescents, pregnant women, and the elderly. Postgrad Med 2004; 115(4): 39–44, 47–50PubMedCrossRefGoogle Scholar
  105. 105.
    Blumenfeld A. Clinical approaches to migraine prophylaxis. Am J Manag Care 2005; 11 (2 Suppl.): 55S–61SGoogle Scholar
  106. 106.
    Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ 1997; 156(9): 1273–87PubMedGoogle Scholar
  107. 107.
    Morey SS. Guidelines on migraine: part 5. Recommendations for specific prophylactic drugs. Am Fam Physician 2000; 62(11): 2535–9PubMedGoogle Scholar
  108. 108.
    Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [online]. Available from URL: http://www.aan.com/professionals/practice/guideline/index.cfm [Accessed 2006 May 19]
  109. 109.
    Geraud G, Lanteri-Minet M, Lucas C, et al., on behalf of the French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004; 26(8): 1305–18PubMedCrossRefGoogle Scholar
  110. 110.
    Landy SH, Lobo BL. Migraine treatment throughout the life-cycle. Expert Rev Neurother 2005; 5(3): 343–53PubMedCrossRefGoogle Scholar
  111. 111.
    Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol 2005; 18(3): 305–10PubMedCrossRefGoogle Scholar
  112. 112.
    Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol 2005; 18(3): 289–92PubMedCrossRefGoogle Scholar
  113. 113.
    Lucetti C, Nuti A, Pavese N, et al. Flunarizine in migraine prophylaxis: predictive factors for a positive response. Cephalalgia 1998; 18(6): 349–52PubMedCrossRefGoogle Scholar
  114. 114.
    Schmidt R, Oestreich W. Flunarizine in migraine prophylaxis: the clinical experience. J Cardiovasc Pharmacol 1991; 18Suppl. 8: S21–6PubMedGoogle Scholar
  115. 115.
    Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995; 35(8): 470–1PubMedCrossRefGoogle Scholar
  116. 116.
    Montgomery L. Are angiotensin-converting enzyme (ACE) inhibitors effective in preventing migraine in nonhypertensive patients? J Fam Pract 2001; 50(4): 299PubMedGoogle Scholar
  117. 117.
    Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322(7277): 19–22PubMedCrossRefGoogle Scholar
  118. 118.
    Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289(1): 65–9PubMedCrossRefGoogle Scholar
  119. 119.
    Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; (3): CD003226Google Scholar
  120. 120.
    Yoon MS, Savidou I, Diener HC, et al. Evidence-based medicine in migraine prevention. Expert Rev Neurother 2005; 5(3): 333–41PubMedCrossRefGoogle Scholar
  121. 121.
    Spierings EL. Mechanism of migraine and action of antimigraine medications. Med Clin North Am 2001; 85(4): 943–58PubMedCrossRefGoogle Scholar
  122. 122.
    McCrory DC, Matchar DB, Gray RN, et al. Evidence-based guidelines for migraine headache: overview of program description and methodology [online]. Available from URL: http://www.aan.com/professionals/practice/guideline/index.cfm [Accessed 2006 May 19]
  123. 123.
    Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52(3): 237–43PubMedCrossRefGoogle Scholar
  124. 124.
    Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; (2): CD003225Google Scholar
  125. 125.
    Zesiewicz TA, Elble R, Louis ED, et al., on behalf of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005; 64(12): 2008–20PubMedCrossRefGoogle Scholar
  126. 126.
    Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. Pharmacopsychiatry 1996; 29(6): 201–11PubMedCrossRefGoogle Scholar
  127. 127.
    Fullerton T. Recent advances in the understanding and treatment of migraine. Pharmacy Pract 1993; 6: 53–270Google Scholar
  128. 128.
    Lance JW. Treatment of migraine. Lancet 1992; 339(8803): 1207–9PubMedCrossRefGoogle Scholar
  129. 129.
    Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003; 7(1): 51–4PubMedCrossRefGoogle Scholar
  130. 130.
    Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15(1): 15–28PubMedCrossRefGoogle Scholar
  131. 131.
    Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches: the role of antidepressants. Neurol Sci 2004; 25Suppl. 3: 171S–5SCrossRefGoogle Scholar
  132. 132.
    Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 2004; 8(2): 91–5PubMedCrossRefGoogle Scholar
  133. 133.
    Oguzhanoglu A, Sahiner T, Kurt T, et al. Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. Cephalalgia 1999; 19(5): 531–2PubMedCrossRefGoogle Scholar
  134. 134.
    Landy S, McGinnis J, Curlin D, et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999; 39(1): 28–32PubMedCrossRefGoogle Scholar
  135. 135.
    Moja P, Cusi C, Sterzi R, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; (3): CD002919Google Scholar
  136. 136.
    Adelman LC, Adelman JU, Von Seggern R, et al. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000; 40(7): 572–80PubMedCrossRefGoogle Scholar
  137. 137.
    Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45(2): 144–52PubMedCrossRefGoogle Scholar
  138. 138.
    Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107(1): 44–8PubMedCrossRefGoogle Scholar
  139. 139.
    Finfgeld DL. Serotonin syndrome and the use of SSRIs. J Psychosoc Nurs Ment Health Serv 2004; 42(2): 16–20PubMedGoogle Scholar
  140. 140.
    van Zwieten PA. Protective effects of calcium antagonists in different organs and tissues. Am Heart J 1993; 125 (2 Pt 2): 566–71PubMedCrossRefGoogle Scholar
  141. 141.
    Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004; 47(1): 34–57PubMedCrossRefGoogle Scholar
  142. 142.
    Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160mg daily [published erratum appears in Cephalalgia 2002; 22 (6): 488]. Cephalalgia 2002; 22(3): 209–21PubMedCrossRefGoogle Scholar
  143. 143.
    Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005; 25(11): 1048–53PubMedCrossRefGoogle Scholar
  144. 144.
    Verspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia 1996; 16(5): 328–36PubMedCrossRefGoogle Scholar
  145. 145.
    Daniel JR, Mauro VF. Extrapyramidal symptoms associated with calcium-channel blockers. Ann Pharmacother 1995; 29(1): 73–5PubMedGoogle Scholar
  146. 146.
    Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 1997; 12(1): 107–10PubMedCrossRefGoogle Scholar
  147. 147.
    Facchinetti F, Sances G, Bakalakis C, et al. Neuroendocrine effects of flunarizine treatment in postmenopausal women. Cephalalgia 1985; 5Suppl. 2: 187–8PubMedGoogle Scholar
  148. 148.
    Spierings EL, Messinger HB. Flunarizine vs. pizotifen in migraine prophylaxis: a review of comparative studies. Cephalalgia 1988; 8Suppl. 8: 27–30PubMedGoogle Scholar
  149. 149.
    Mylecharane EJ. 5-HT2 receptor antagonists and migraine therapy. J Neurol 1991; 238Suppl. 1: 45S–52SCrossRefGoogle Scholar
  150. 150.
    Silberstein SD. Methysergide. Cephalalgia 1998; 18(7): 421–35PubMedCrossRefGoogle Scholar
  151. 151.
    Diener HC, Kaube H, Limmroth VA. Practical guide to the management and prevention of migraine. Drugs 1998; 56(5): 811–24PubMedCrossRefGoogle Scholar
  152. 152.
    Wheeler SD. Antiepileptic drug therapy in migraine headache. Curr Treat Options Neurol 2002; 4(5): 383–94PubMedCrossRefGoogle Scholar
  153. 153.
    Steinberg J. Anticonvulsant medications for migraine prevention. Am Fam Physician 2005; 71(9): 1699–700PubMedGoogle Scholar
  154. 154.
    Freitag FG. Divalproex in the treatment of migraine. Psychopharmacol Bull 2003; 37Suppl. 2: 98–115PubMedGoogle Scholar
  155. 155.
    Silberstein SD. Topiramate in migraine prevention. Headache 2005; 45Suppl. 1: 57S–65SCrossRefGoogle Scholar
  156. 156.
    Young WB, Hopkins MM, Shechter AL, et al. Topiramate: a case series study in migraine prophylaxis. Cephalalgia. 2002; 22(8): 659–63PubMedCrossRefGoogle Scholar
  157. 157.
    Topiramate (Topamax) for prevention of migraine. Med Lett Drugs Ther 2005; 47(1201): 9–10Google Scholar
  158. 158.
    Mattson RH. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis 2004; 1Suppl. 1: 10S–7SGoogle Scholar
  159. 159.
    Ondo WG, Jankovic J, Connor GS, et al., on behalf of the Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006; 66(5): 672–7PubMedCrossRefGoogle Scholar
  160. 160.
    Cereza G, Pedros C, Garcia N, et al. Topiramate in non-approved indications and acute myopia or angle closure glaucoma. Br J Clin Pharmacol 2005; 60(5): 578–9PubMedCrossRefGoogle Scholar
  161. 161.
    D’Andrea G, Granella F, Cadaldini M, et al. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19(1): 64–6PubMedCrossRefGoogle Scholar
  162. 162.
    Lampl C, Buzath A, Klinger D, et al. Lamotrigine in the prophylactic treatment of migraine aura: a pilot study. Cephalalgia 1999; 19(1): 58–63PubMedCrossRefGoogle Scholar
  163. 163.
    Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17(2): 109–12PubMedCrossRefGoogle Scholar
  164. 164.
    Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J 1970; 44(4): 75–80PubMedGoogle Scholar
  165. 165.
    Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci 2004; 25Suppl. 3: 161S–6SCrossRefGoogle Scholar
  166. 166.
    Schoonman GG, Wiendels NJ, Ferrari MD. Gabapentin in migraine prophylaxis: is it effective and well tolerated? [letter]. Headache 2002; 42(3): 235PubMedGoogle Scholar
  167. 167.
    Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41(2): 119–28PubMedCrossRefGoogle Scholar
  168. 168.
    Freitag FG, Diamond S, Solomon GD. The prophylaxis of migraine with the GABA-agonist tiagabine: a clinical report [abstract]. Headache 1999; 19: 354Google Scholar
  169. 169.
    Drake Jr ME, Greathouse NI, Renner JB, et al. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004; 27(6): 278–80PubMedCrossRefGoogle Scholar
  170. 170.
    Cochran JW. Levetiracetam as migraine prophylaxis. Clin J Pain 2004; 20(3): 198–9PubMedCrossRefGoogle Scholar
  171. 171.
    Capuano A, Vollono C, Mei D, et al. Antiepileptic drugs in migraine prophylaxis: state of the art. Clin Ter 2004; 155(2–3): 79–87PubMedGoogle Scholar
  172. 172.
    Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004; 63 (10 Suppl. 4): 40S–8SCrossRefGoogle Scholar
  173. 173.
    Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003; 25(10): 2506–38PubMedCrossRefGoogle Scholar
  174. 174.
    Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004; 3(10): 618–21PubMedCrossRefGoogle Scholar
  175. 175.
    Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr Pain Headache Rep 2004; 8(3): 244–50PubMedCrossRefGoogle Scholar
  176. 176.
    Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005; 41(9): 589–97CrossRefGoogle Scholar
  177. 177.
    Armijo JA, Shushtarian M, Valdizan EM, et al. Ion channels and epilepsy. Curr Pharm Des 2005; 11(15): 1975–2003PubMedCrossRefGoogle Scholar
  178. 178.
    Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6(2): 57–75PubMedGoogle Scholar
  179. 179.
    Lieberman DZ, Goodwin FK. Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. Curr Psychiatry Rep 2004; 6(6): 459–65PubMedCrossRefGoogle Scholar
  180. 180.
    Muzina DJ, Elhaj O, Gajwani P, et al. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand Suppl 2005; (426): 21–8Google Scholar
  181. 181.
    Rahimtoola H, Buurma H, Tijssen CC, et al. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy: a pilot study. Pharmacoepidemiol Drug Saf 2004; 13(1): 41–7PubMedCrossRefGoogle Scholar
  182. 182.
    Diener HC, Hartung E, Chrubasik J, et al., on behalf of the Study Group. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine: a randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001; 21(2): 120–8PubMedCrossRefGoogle Scholar
  183. 183.
    Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30(11): 710–5PubMedCrossRefGoogle Scholar
  184. 184.
    Solomon GD, Kunkel RS. Flurbiprofen in the prophylaxis of migraine. Cleve Clin J Med 1993; 60(1): 43–8PubMedGoogle Scholar
  185. 185.
    Carrieri PB, Orefice G, Sorge F. A double-blind placebo-controlled trial of indobufen in the prophylaxis of migraine. Acta Neurol Scand 1988; 77(6): 433–6PubMedCrossRefGoogle Scholar
  186. 186.
    Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis. Headache 1974; 14(2): 96–100PubMedCrossRefGoogle Scholar
  187. 187.
    Pradalier A, Vincent D. Migraine and non-steroidal anti-inflammatory agents [in French]. Pathol Biol (Paris) 1992; 40(4): 397–405Google Scholar
  188. 188.
    Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolfenamic acid: a comparative double-blind crossover study between tolfenamic acid and placebo. Acta Neurol Scand 1982; 66(1): 105–11PubMedCrossRefGoogle Scholar
  189. 189.
    Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand 1986; 73(5): 490–2PubMedCrossRefGoogle Scholar
  190. 190.
    Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006; 29(2): 119–32PubMedCrossRefGoogle Scholar
  191. 191.
    Zwart JA, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003; 61(2): 160–4PubMedCrossRefGoogle Scholar
  192. 192.
    Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre: clinical characteristics and treatment outcomes. Cephalalgia 2004; 24(6): 483–90PubMedCrossRefGoogle Scholar
  193. 193.
    Relja G, Granato A, Maria Antonello R, et al. Headache induced by chronic substance use: analysis of medication overused and minimum dose required to induce headache. Headache 2004; 44(2): 148–53PubMedCrossRefGoogle Scholar
  194. 194.
    Limmroth V, Katsarava Z. Medication overuse headache. Curr Opin Neurol 2004; 17(3): 301–6PubMedCrossRefGoogle Scholar
  195. 195.
    Colas R, Munoz P, Temprano R, et al. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004; 62(8): 1338–42PubMedCrossRefGoogle Scholar
  196. 196.
    Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine: a double-blind placebo-controlled study. Cephalalgia 1996; 16(6): 436–40PubMedCrossRefGoogle Scholar
  197. 197.
    Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004; (1): CD002286Google Scholar
  198. 198.
    Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004; 11(7): 475–7PubMedCrossRefGoogle Scholar
  199. 199.
    Mauskop A. Alternative therapies in headache: is there a role? Med Clin North Am 2001; 85(4): 1077–84PubMedCrossRefGoogle Scholar
  200. 200.
    Bianchi A, Salomone S, Caraci F, et al. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm 2004; 69: 297–312PubMedCrossRefGoogle Scholar
  201. 201.
    Rios J, Passe MM. Evidenced-based use of botanicals, minerals, and vitamins in the prophylactic treatment of migraines. J Am Acad Nurse Pract 2004; 16(6): 251–6PubMedCrossRefGoogle Scholar
  202. 202.
    Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44(9): 885–90PubMedCrossRefGoogle Scholar
  203. 203.
    Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64(4): 713–5PubMedCrossRefGoogle Scholar
  204. 204.
    Coenzyme Q10 [published erratum appears in Med Lett Drugs Ther 2006; 48 (1230): 24]. Med Lett Drugs Ther 2006; 48(1229): 19–20Google Scholar
  205. 205.
    Sandor PS, Afra J. Nonpharmacologic treatment of migraine. Curr Pain Headache Rep 2005; 9(3): 202–5PubMedCrossRefGoogle Scholar
  206. 206.
    Troost BT. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev Neurother 2004; 4(1): 27–31PubMedCrossRefGoogle Scholar
  207. 207.
    Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24(10): 838–43PubMedCrossRefGoogle Scholar
  208. 208.
    Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol 2004; 251Suppl. 1: 81–111Google Scholar
  209. 209.
    Conway S, Delplanche C, Crowder J, et al. Botox therapy for refractory chronic migraine. Headache 2005; 45(4): 355–7PubMedCrossRefGoogle Scholar
  210. 210.
    Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43Suppl. 1: 9S–15SCrossRefGoogle Scholar
  211. 211.
    Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107(1–2): 125–33PubMedCrossRefGoogle Scholar
  212. 212.
    Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44(1): 35–42PubMedCrossRefGoogle Scholar
  213. 213.
    Blumenfeld AM, Binder W, Silberstein SD, et al. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003; 43(8): 884–91PubMedCrossRefGoogle Scholar
  214. 214.
    Nissan GR, Diamond ML. Advances in migraine treatment. J Am Osteopath Assoc 2005; 105 (4 Suppl. 2): 9S–15SPubMedGoogle Scholar
  215. 215.
    Mathew NT, Kaup AO. The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol 2002; 4(5): 365–73PubMedCrossRefGoogle Scholar
  216. 216.
    Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993; 17(1): 31–7PubMedCrossRefGoogle Scholar
  217. 217.
    Johnson CJ. Headache in women. Prim Care 2004; 31(2): 417–28PubMedCrossRefGoogle Scholar
  218. 218.
    Calhoun AH. Migraine and menopause [letter]. Headache 2004; 44(1): 106PubMedCrossRefGoogle Scholar
  219. 219.
    Matharu MS, Levy MJ, Goadsby PJ. Understanding migraine in women [published erratum appears in Practitioner 2002; 246 (1638): 618]. Practitioner 2002; 246(1633): 272–8PubMedGoogle Scholar
  220. 220.
    Fettes I. Migraine in the menopause. Neurology 1999; 53 (4 Suppl. 1): 29S–33SGoogle Scholar
  221. 221.
    Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women [published erratum appears in Headache 2003; 43 (2): 172; Headache 2003; 43 (3): 310]. Headache 2002; 42(9): 924–9PubMedCrossRefGoogle Scholar
  222. 222.
    Silberstein SD. Hormone-related headache. Med Clin North Am 2001; 85(4): 1017–35PubMedCrossRefGoogle Scholar
  223. 223.
    Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc 2004; 10(3): 95–102PubMedGoogle Scholar
  224. 224.
    Felmeden DC, Lip GY. Hormone replacement therapy and hypertension. Blood Press 2000; 9(5): 246–9PubMedCrossRefGoogle Scholar
  225. 225.
    Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9(1): 6–15PubMedCrossRefGoogle Scholar
  226. 226.
    Gambacciani M, Monteleone P, Sacco A, et al. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 2003; 17(1): 139–47PubMedCrossRefGoogle Scholar
  227. 227.
    Prelevic GM, Kocjan T, Markou A. Hormone replacement therapy in postmenopausal women. Minerva Endocrinol 2005; 30(1): 27–36PubMedGoogle Scholar
  228. 228.
    Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288(7): 872–81PubMedCrossRefGoogle Scholar
  229. 229.
    Ashkenazi A, Silberstein SD. Hormone-related headache: pathophysiology and treatment. CNS Drugs 2006; 20(2): 125–41PubMedCrossRefGoogle Scholar
  230. 230.
    Kudrow L. The relationship of headache frequency to hormone use in migraine. Headache 1975; 15(1): 36–40PubMedCrossRefGoogle Scholar
  231. 231.
    Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73(4): 606–12PubMedGoogle Scholar
  232. 232.
    Nand SL, Webster MA, Baber R, et al. Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group. Climacteric 1998; 1(3): 211–8PubMedCrossRefGoogle Scholar
  233. 233.
    Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38(2): 157–63PubMedCrossRefGoogle Scholar
  234. 234.
    Greenblatt RB. The use of androgens in the menopause and other gynecic disorders. Obstet Gynecol Clin North Am 1987; 14(1): 251–68PubMedGoogle Scholar
  235. 235.
    Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1): 799–805PubMedCrossRefGoogle Scholar
  236. 236.
    Adler G, Young D, Galant R, et al. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. Gynecol Obstet Invest 2005; 59(4): 212–9PubMedCrossRefGoogle Scholar
  237. 237.
    Silberstein SD. Headache and female hormones: what you need to know. Curr Opin Neurol 2001; 14(3): 323–33PubMedCrossRefGoogle Scholar
  238. 238.
    Merle L, Laroche ML, Dantoine T, et al. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005; 22(5): 375–92PubMedCrossRefGoogle Scholar
  239. 239.
    Ward TN. Headache disorders in the elderly. Curr Treat Options Neurol 2002; 4(5): 403–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Paola Sarchielli
    • 1
  • Maria Luisa Mancini
    • 1
  • Paolo Calabresi
    • 1
  1. 1.Department of Medical and Surgical Specialties and Public Health, Neurologic ClinicUniversity of PerugiaPerugiaItaly

Personalised recommendations